Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons

Experimental Neurology

Volumn 219, Issue 2, 2009, Pages 499-506

  Piltonen, Marjo ^a   Bespalov, Maxim M ^b   Ervasti, Dagmar ^a   Matilainen, Tero ^a   Sidorova, Yulia A ^b   Rauvala, Heikki ^a   Saarma, Mart ^b   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

6 OHDA; GDNF; HB GAM; Heparan sulphates; Neuroprotection; Pleiotrophin; Tissue distribution

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLEIOTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG RESPONSE; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; SEQUENCE DELETION; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; TYROSINE 3-MONOOXYGENASE;

EID: 69749119998     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.07.002     Document Type: Article

References (50)

1. Alfano I., Vora P., Mummery R.S., Mulloy B., and Rider C.C. The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochem. J. 404 (2007) 131-140
2. Baloh R.H., Tansey M.G., Johnson Jr. E.M., and Milbrandt J. Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. J. Biol. Chem. 275 (2000) 3412-3420
3. Barnett M.W., Fisher C.E., Perona-Wright G., and Davies J.A. Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J. Cell. Sci. 115 (2002) 4495-4503
4. Bishop J.R., Schuksz M., and Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446 (2007) 1030-1037
5. Davies J.A., Yates E.A., and Turnbull J.E. Structural determinants of heparan sulphate modulation of GDNF signalling. Growth Factors 21 (2003) 109-119
6. Eketjäll S., Fainzilber M., Murray-Rust J., and Ibanez C.F. Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J. 18 (1999) 5901-5910
7. Ferrario J.E., Taravini I.R., Mourlevat S., Stefano A., Delfino M.A., Raisman-Vozari R., Murer M.G., Ruberg M., and Gershanik O. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J. Neurochem. 90 (2004) 1348-1358
8. Ferrario J.E., Rojas-Mayorquin A.E., Saldana-Ortega M., Salum C., Gomes M.Z., Hunot S., and Raisman-Vozari R. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by l-DOPA in striatal medium spiny neurons of parkinsonian rats. J. Neurochem. 107 (2008) 443-452
9. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
10. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., and Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann. Neurol. 58 (2005) 224-233
11. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
12. Gospodarowicz D., and Cheng J. Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128 (1986) 475-484
13. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., Oldfield E., and Bankiewicz K.S. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp. Neurol. 168 (2001) 155-161
14. Hida H., Jung C.G., Wu C.Z., Kim H.J., Kodama Y., Masuda T., and Nishino H. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur. J. Neurosci. 17 (2003) 2127-2134
15. Hida H., Masuda T., Sato T., Kim T.S., Misumi S., and Nishino H. Pleiotrophin promotes functional recovery after neural transplantation in rats. NeuroReport 18 (2007) 179-183
16. Hu, S., 2001. Truncated glial cell line-derived neurotrophic factor. Patent no. US 6,184,200 B1
17. Jing S., Wen D., Yu Y., Holst P.L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J.C., Hu S., Altrock B.W., and Fox G.M. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85 (1996) 1113-1124
18. Kääriäinen T.M., Piltonen M., Ossola B., Kekki H., Lehtonen S., Nenonen T., Lecklin A., Raasmaja A., and Männistö P.T. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res. 1203 (2008) 149-159
19. Keinänen K., Jouppila A., and Kuusinen A. Characterization of the kainate-binding domain of the glutamate receptor GluR-6 subunit. Biochem. J. 330 Pt. 3 (1998) 1461-1467
20. Kinnunen A., Niemi M., Kinnunen T., Kaksonen M., Nolo R., and Rauvala H. Heparan sulphate and HB-GAM (heparin-binding growth-associated molecule) in the development of the thalamocortical pathway of rat brain. Eur. J. Neurosci. 11 (1999) 491-502
21. Kirik D., Rosenblad C., and Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
22. Kirik D., Rosenblad C., and Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12 (2000) 3871-3882
23. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
24. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
25. Lin L.F., Zhang T.J., Collins F., and Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63 (1994) 758-768
26. Marchionini D.M., Lehrmann E., Chu Y., He B., Sortwell C.E., Becker K.G., Freed W.J., Kordower J.H., and Collier T.J. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 1147 (2007) 77-88
27. Meng X., Lindahl M., Hyvönen M.E., Parvinen M., de Rooij D.G., Hess M.W., Raatikainen-Ahokas A., Sainio K., Rauvala H., Lakso M., Pichel J.G., Westphal H., Saarma M., and Sariola H. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 287 (2000) 1489-1493
28. Mi R., Chen W., and Hoke A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4664-4669
29. Mijatovic J., Airavaara M., Planken A., Auvinen P., Raasmaja A., Piepponen T.P., Costantini F., Ahtee L., and Saarma M. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J. Neurosci. 27 (2007) 4799-4809
30. Moore M.W., Klein R.D., Farinas I., Sauer H., Armanini M., Phillips H., Reichardt L.F., Ryan A.M., Carver-Moore K., and Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382 (1996) 76-79
31. Paratcha G., Ledda F., and Ibanez C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113 (2003) 867-879
32. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., and Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11 (2008) 755-761
33. Pichel J.G., Shen L., Sheng H.Z., Granholm A.C., Drago J., Grinberg A., Lee E.J., Huang S.P., Saarma M., Hoffer B.J., Sariola H., and Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382 (1996) 73-76
34. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem. Soc. Trans. 34 (2006) 422-426
35. Raulo E., Julkunen I., Merenmies J., Pihlaskari R., and Rauvala H. Secretion and biological activities of heparin-binding growth-associated molecule. Neurite outgrowth-promoting and mitogenic actions of the recombinant and tissue-derived protein. J. Biol. Chem. 267 (1992) 11408-11416
36. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. 8 (1989) 2933-2941
37. Rauvala H., and Peng H.B. HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Prog. Neurobiol. 52 (1997) 127-144
38. Rickard S.M., Mummery R.S., Mulloy B., and Rider C.C. The binding of human glial cell line-derived neurotrophic factor to heparin and heparan sulfate: importance of 2-O-sulfate groups and effect on its interaction with its receptor, GFRalpha1. Glycobiology 13 (2003) 419-426
39. Sainio K., Suvanto P., Davies J., Wartiovaara J., Wartiovaara K., Saarma M., Arumäe U., Meng X., Lindahl M., Pachnis V., and Sariola H. Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric epithelium. Development 124 (1997) 4077-4087
40. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., and Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 202 (2006) 497-505
41. Sanchez M.P., Silos-Santiago I., Frisen J., He B., Lira S.A., and Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382 (1996) 70-73
42. Sariola H., and Saarma M. Novel functions and signalling pathways for GDNF. J. Cell. Sci. 116 (2003) 3855-3862
43. Sauer H., Rosenblad C., and Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8935-8939
44. Schlessinger J., Lax I., and Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. Cell 83 (1995) 357-360
45. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
46. Tanaka M., Xiao H., and Kiuchi K. Heparin facilitates glial cell line-derived neurotrophic factor signal transduction. NeuroReport 13 (2002) 1913-1916
47. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
48. Treanor J.J., Goodman L., de Sauvage F., Stone D.M., Poulsen K.T., Beck C.D., Gray C., Armanini M.P., Pollock R.A., Hefti F., Phillips H.S., Goddard A., Moore M.W., Buj-Bello A., Davies A.M., Asai N., Takahashi M., Vandlen R., Henderson C.E., and Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature 382 (1996) 80-83
49. Trupp M., Arenas E., Fainzilber M., Nilsson A.S., Sieber B.A., Grigoriou M., Kilkenny C., Salazar-Grueso E., Pachnis V., Arumäe U., Saarma M., and Ibañez C.F. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 (1996) 785-789
50. Winkler C., Sauer H., Lee C.S., and Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16 (1996) 7206-7215